Skip to main content
logo
LSL Pharma Group Inc. (TSXV:LSL)
Canada flag Canada · Delayed Price · Currency is CAD
0.3500
-0.0050 (-1.41%)
At close: Aug 10, 2026

LSL Pharma Group Financials Overview

Millions CAD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jul '21
Revenue
34.4228.7417.7510.038.21-
Revenue Growth
70.31%61.96%76.98%22.08%--
Gross Profit
3.775.15.351.65-2.17-
Operating Income
-4.4-2.130.82-2-13.94-0.06
Net Income
-5.48-2.823.32-8.47-8.060.09
Earnings Per Share
-0.03-0.020.03-0.11-0.120.00
EPS Growth
------

Revenue by Segment
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '25 Dec '24 Dec '23
CMO
25.525.510.544.87
Eye-care Division
3.253.257.215.16
Total
28.7428.7417.7510.03

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jul '21
Cash & Investments
0.770.550.30.010.010
Total Debt
43.6938.3521.8716.2715.90.11
Net Cash (Debt)
-42.93-37.8-21.57-16.26-15.89-0.11
Net Cash Growth
------
Net Cash Per Share
-0.23-0.32-0.20-0.20-0.24-0.01

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-5.5-2.45-1.65-7.07-3.16
Capital Expenditures
-1.89-2.02-3.12-0.66-1
Free Cash Flow
-7.39-4.46-4.77-7.73-4.16
Free Cash Flow Growth
-----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jul '21
Gross Margin
10.94%17.75%30.13%16.40%-26.44%-
Operating Margin
-12.77%-7.41%4.64%-19.93%-169.70%-
Pretax Margin
-17.79%-10.04%18.97%-84.48%-98.15%-
Profit Margin
-17.79%-9.81%18.69%-84.48%-98.15%-
FCF Margin
-21.47%-15.53%-26.89%-77.04%-50.66%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2022
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Jul '22
PE Ratio
--13.67---
PS Ratio
1.571.432.443.99--